EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 37 / Numéro 5 (Mai 2021) Med Sci (Paris), 37 5 (2021) 507-518 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 37, Numéro 5, Mai 2021
La révolution médicale du dépistage néonatal – Une aventure médicale scientifique et sociétale
Page(s) 507 - 518
Section La révolution médicale du dépistage néonatal – Une aventure médicale scientifique et sociétale
DOI https://doi.org/10.1051/medsci/2021057
Publié en ligne 18 mai 2021
  1. Recommandation de la Haute autorité de santé. Évaluation de l’extension du dépistage néonatal à une ou plusieurs erreurs innées du métabolisme par spectrométrie de masse en tandem. 1er volet: déficit en MCAD. Saint-Denis : HAS, 2011. https://www.has-sante.fr/jcms/c_1069254/fr/evaluation-de-l-extension-du-depistage-neonatal-a-une-ou-plusieurs-erreurs-innees-du-metabolisme-par-spectrometrie-de-masse-en-tandem-1er-volet-deficit-en-mcad. [Google Scholar]
  2. Arrêté du 12 novembre 2020 modifiant l’arrêté du 22 février 2018 relatif à l’organisation du programme national de dépistage néonatal recourant à des examens de biologie médicale. https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042521346. [Google Scholar]
  3. Rapport de la Haute autorité de santé. Dépistage néonatal : quelles maladies dépister ? Paris : HAS, 2020. https://www.has-sante.fr/jcms/p_3149627/fr/depistage-neonatal-quelles-maladies-depister. [Google Scholar]
  4. Saudubray JM, Baumgartner M, Walter J Inborn metabolic diseases: diagnosis and treatment 2016 ; 6th ed. Berlin-Heidelberg Springer [Google Scholar]
  5. Janck JM, Maier EM, Reib DD, et al. The domain-specific and temperature-dependent protein misfolding phenotype of variant medium-chain acyl-CoA dehydrogenase. PLoS One 2014 ; 9 : e107094. [Google Scholar]
  6. Derks TGJ, Boer TS, van Assen A, et al. Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency. J Inherit Metab Dis 2008 ; 31 : 88–96. [CrossRef] [PubMed] [Google Scholar]
  7. Couce ML, Sanchez-Pintos P, Diogo L, et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency. Orphanet J Rare Dis 2013 ; 8 : 102. [CrossRef] [PubMed] [Google Scholar]
  8. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003 ; 348 : 2304. [CrossRef] [PubMed] [Google Scholar]
  9. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inhertit Metab Dis 2006 ; 29 : 76–85. [Google Scholar]
  10. McHugh DMS, Cameron CA, Abdenur JE, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011 ; 13 : 230–254. [CrossRef] [PubMed] [Google Scholar]
  11. Jager EA, Kuijpers MM, Bosch AM, et al. A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands. J Inherit Metab Dis 2019 ; 42 : 890–897. [CrossRef] [PubMed] [Google Scholar]
  12. Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA, et al. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 2010 ; 99 : 263–268. [CrossRef] [PubMed] [Google Scholar]
  13. Feillet F, Ogier H, Cheillan D, Aquaviva C, et al. Déficit en acyl-CoA-déshydrogénase des acides gras à chaîne moyenne (MCAD): consensus français pour le dépistage, le diagnostic, et la prise en charge. Arch Pediatr 2012 ; 19 : 184–193. [CrossRef] [PubMed] [Google Scholar]
  14. Wilcken B, Haas M, Joy P, et al. A. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009 ; 124 : e241–e248. [CrossRef] [PubMed] [Google Scholar]
  15. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Lancet 2007 ; 369 : 37–42. [CrossRef] [PubMed] [Google Scholar]
  16. Nennstiel-Ratzel U, Arenz S, Maier EM, et al. Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c 985A > G identified by neonatal screening. Mol Genet Metab 2005 ; 85 : 157–159. [CrossRef] [PubMed] [Google Scholar]
  17. Anderson DR, Viau K, Botto LD, et al. Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2020; 129 : 13–9. [CrossRef] [PubMed] [Google Scholar]
  18. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 1998 ; 79 : 116–119. [CrossRef] [PubMed] [Google Scholar]
  19. Derks TG, Reijngoud DJ, Waterham HR, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. J Pediatr 2006 ; 148 : 665–670. [CrossRef] [PubMed] [Google Scholar]
  20. Lindner M, Gramer M, Haege G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases. Report of 10 years from South-West Germany. Orphanet J Rare Dis 2011 ; 6 : 44. [CrossRef] [PubMed] [Google Scholar]
  21. Grosse SD, Thompson JD, Ding Y, Glass M. The use of economic evaluation to inform newborn screening policy decisions: the Washington state experience. Milbank Q 2016 ; 94 : 366–391. [CrossRef] [PubMed] [Google Scholar]
  22. Van der Hilst CS. Deks TGJ, Reijngoud DJ, el al. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. J Pediatr 2007 ; 151 : 115–120. [CrossRef] [PubMed] [Google Scholar]
  23. Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 2007 ; 10 : 83–97. [CrossRef] [PubMed] [Google Scholar]
  24. Hamers FF, Rumeau-Pichon C. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France. BMC Pediatr 2012 ; 12 : 60. [CrossRef] [PubMed] [Google Scholar]
  25. Karaceper MD, Khangura SD, Wilson K, et al. Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario. Canada. Orphanet J Rare Dis 2019 ; 14 : 70. [Google Scholar]
  26. Karaceper MD, Chakraborty P, Coyle D, et al. The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet J Rare Dis 2016 ; 11 : 12. [CrossRef] [PubMed] [Google Scholar]
  27. Malvagia S, Forni G, Ombrone D, et al. Development of strategies to decrease false positive results in newborn screening. Int J Neonatal Screen 2020; 6 : 84. [Google Scholar]
  28. Lund AM, Hougaard DM, Simonsen H, et al. Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland: experience and development of a routine program for expanded newborn screening. Mol Genet Metab 2012 ; 107 : 281–293. [CrossRef] [PubMed] [Google Scholar]
  29. Estrella J, Wilcken B, Carpenter K, et al. Expanded newborn screening in New South Wales: missed cases. J Inherit Metab Dis 2014 ; 37 : 881–887. [CrossRef] [PubMed] [Google Scholar]
  30. Matern D, Tortorelli S, Oglesbee D, et al. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004–2007). J Inherit Metab Dis 2007 ; 30 : 585–592. [CrossRef] [PubMed] [Google Scholar]
  31. Okun JG, Gan-Schreier H, Ben-Omran T, et al. Newborn screening for vitamin b 6 non-responsive classical homocystinuria: systematical evaluation of a two-tier strategy. JIMD Reports 2017 ; 32 : 87–94. [CrossRef] [PubMed] [Google Scholar]
  32. Boy N, Mengler K, Thimm E, et al. Newborn screening: a disease-changing intervention for glutaric aciduria type 1. Ann Neurol 2018 ; 83 : 970–979. [CrossRef] [PubMed] [Google Scholar]
  33. Carling RS, Burden D, Hutton I, et al. Introduction of a simple second tier screening test for c5 isobars in dried blood spots: reducing the false positive rate for isovaleric acidaemia in expanded newborn screening. JIMD Reports 2018 ; 38 : 75–80. [CrossRef] [PubMed] [Google Scholar]
  34. Schlune A, Riederer A, Mayatepek E, Ensenauer R. Aspects of newborn screening in isovaleric acidemia. Int J Neonatal Screen 2018 ; 29 : 7. [Google Scholar]
  35. Immonem T, Turanlahti M, Paganus A, et al. Earlier diagnosis and strict diets improve the survival rate and clinical course of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr 2016 ; 105 : 549–554. [CrossRef] [PubMed] [Google Scholar]
  36. Lotz-Havla AS, Roschinger W, Schiergens W, et al. Aspects of newborn screening in isovaleric acidemia. Orphanet J Rare Dis 2018 ; 13 : 122. [CrossRef] [PubMed] [Google Scholar]
  37. Smon A, Lampret BR, Groselj U, et al. Next generation sequencing as a follow-up test in an expanded newborn screening program. Clin Biochem 2018 ; 52 : 48–55. [CrossRef] [PubMed] [Google Scholar]
  38. Yang Y, Wang L, Wang B, et al. Application of next-generation sequencing following tandem mass spectrometry to expand newborn screening for inborn errors of metabolism: a multicenter study. Front Genet 2019 ; 10 : 86. [CrossRef] [PubMed] [Google Scholar]
  39. Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med 2021; https://doi.org/10.1038/s41436-020-01070-0. [PubMed] [Google Scholar]
  40. Munck A, Gauthereau V, Czernichow P. Organisation du dépistage néonatal en France. Med Sci (Paris) 2021; 37 : 457–60. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Loeber JG, Platis D, Zetterström RH, Schielen PJCI. Dépistage néonatal en Europe : évolution depuis, et analyse de la situation actuelle par la Société internationale de dépistage néonatal. Med Sci (Paris) 2010 ; 2021 : 37 441–456. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.